Compare MDXG & TOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDXG | TOI |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | United States | United States |
| Employees | N/A | 641 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 530.2M | 579.9M |
| IPO Year | 2007 | N/A |
| Metric | MDXG | TOI |
|---|---|---|
| Price | $4.12 | $5.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $9.00 | $6.67 |
| AVG Volume (30 Days) | 1.2M | ★ 1.8M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.29 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $418,630,000.00 | N/A |
| Revenue This Year | N/A | $30.15 |
| Revenue Next Year | $13.02 | $25.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.99 | N/A |
| 52 Week Low | $3.03 | $2.32 |
| 52 Week High | $7.99 | $6.11 |
| Indicator | MDXG | TOI |
|---|---|---|
| Relative Strength Index (RSI) | 63.24 | 64.43 |
| Support Level | $3.50 | $3.28 |
| Resistance Level | $5.31 | N/A |
| Average True Range (ATR) | 0.14 | 0.37 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 72.97 | 78.10 |
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.